A prospective, non-interventional, multicenter G-EPOSS study evaluating long-term effectiveness of guselkumab from the real-life G-EPOSS study
Latest Information Update: 17 Mar 2025
Price :
$35 *
At a glance
- Drugs Guselkumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms G-EPOSS
- 01 Mar 2025 Results assessing evaluate the effectiveness and safety of guselkumab, including its impact on skin, health-related quality of life (HRQoL), sexuality, and perceived stigmatization, published in the Journal of the European Academy of Dermatology and Venereology
- 12 May 2023 New trial record